The abstract is read at the publisher; the summary is JClub's.
Dulaglutide (0.75 mg weekly) reduced glycaemic variability in adolescents with transfusion-dependent β-thalassaemia–induced diabetes, with CV falling from 39.45±3.97% to 35.05±4.30% (p<0.001).
- Why it matters: Adolescents with TDT-induced diabetes face chronic iron overload and elevated cardiometabolic risk, yet dulaglutide’s comparative effects on glycaemia, pancreatic reserve, iron load, and lipids versus insulin were unclear.
- What they did: In the open-label, parallel-group, randomised-controlled DIADEMA trial in Cairo, 80 participants (age 10–18) received dulaglutide or basal-bolus insulin for 24 weeks, with masked outcome assessment using fasting labs and CGM-derived metrics.
- The result: Compared with insulin, dulaglutide improved CV and time above range, increased fasting C-peptide and time in range, and lowered fasting glucose, HbA1c, fructosamine, total cholesterol, and serum ferritin; no serious adverse events occurred.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.